| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 22, 2016First polymer-based, drug-eluting stent designed to treat peripheral lesions above the knee approved in Europe; IMPERIAL trial initiated to seek regulatory approvals in U.S. and Asia
Boston Scientific (NYSE: BSX) today announced that the Eluvia™ Drug-Eluting Vascular Stent System has received CE Mark and is commencing commercialization immediately in the European Union and...
Jan 12, 2016Single-Use System for stone removal eliminates maintenance, reprocessing and sterilizationBoston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launch of the LithoVueTM Single-Use Digital Flexible Ureteroscope for minimally invasive endoscopic procedures to...
-
Dec 11, 2015
Final results evaluating the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate that the device provides more than 70 percent greater...
-
Nov 19, 2015First Implants Occur in Europe, Commencing Limited Market Release
Boston Scientific (NYSE: BSX) today announced that the first implants of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device – the latest generation of the WATCHMAN Device –...
-
Nov 9, 2015Topline data confirming peri-procedural safety of left atrial appendage (LAA) occlusion with the WATCHMAN™ Left Atrial Appendage (LAA) Closure device was presented in an oral session during the American Heart Association (AHA) Scientific Sessions.
This is the first study to collect real-world WATCHMAN LAA Closure Device experience outside of selected populations in randomized trials. Results from the prospective, multi-centre EWOLUTION...